| Dr Charles Cory Rosenstein, MD | |
|
29 Hospital Plaza, Suite 602, Stamford, CT 06902-3602 | |
| (203) 276-4884 | |
| (203) 276-8418 |
| Full Name | Dr Charles Cory Rosenstein |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 39 Years |
| Location | 29 Hospital Plaza, Stamford, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952310245 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 31582 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stamford Hospital | Stamford, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stamford Health Medical Group Inc | 6901099746 | 355 |
News Archive
While Zika remains a hot topic in the news, a new survey by Mayo Clinic reveals that Americans believe the country's most significant health care challenge is cancer.
Every year, in Germany alone, around 7,000 people wait for a new cornea to save their eyesight.
"The nation's uninsured — a growing class of people whose recession-fed ranks have swelled to 46.3 million — are central to the health care debate in Washington and the questions about how and whether to get them covered are as vexing and emotional as they come," USA Today reports. "While the nation waits for Congress and the White House to come up with answers, those who live without insurance say they are waiting scared."
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
A 64-year-old female patient with mediastinal metastasis recently became the first in Latin America to receive Elekta VMAT radiotherapy treatment enhanced with Monaco® planning software. Using the arc-based Elekta VMAT delivery method, Monaco displays how the radiation dose should be applied — its distribution and strength on the target. The result is a therapy that not only is rapid, but also fine-tuned to treat cancer and avoid healthy tissues.
› Verified 8 days ago
| Entity Name | Stamford Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154633980 PECOS PAC ID: 6901099746 Enrollment ID: O20101025000743 |
News Archive
While Zika remains a hot topic in the news, a new survey by Mayo Clinic reveals that Americans believe the country's most significant health care challenge is cancer.
Every year, in Germany alone, around 7,000 people wait for a new cornea to save their eyesight.
"The nation's uninsured — a growing class of people whose recession-fed ranks have swelled to 46.3 million — are central to the health care debate in Washington and the questions about how and whether to get them covered are as vexing and emotional as they come," USA Today reports. "While the nation waits for Congress and the White House to come up with answers, those who live without insurance say they are waiting scared."
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
A 64-year-old female patient with mediastinal metastasis recently became the first in Latin America to receive Elekta VMAT radiotherapy treatment enhanced with Monaco® planning software. Using the arc-based Elekta VMAT delivery method, Monaco displays how the radiation dose should be applied — its distribution and strength on the target. The result is a therapy that not only is rapid, but also fine-tuned to treat cancer and avoid healthy tissues.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles Cory Rosenstein, MD 29 Hospital Plaza, Suite 602, Stamford, CT 06902-3602 Ph: (203) 276-4884 | Dr Charles Cory Rosenstein, MD 29 Hospital Plaza, Suite 602, Stamford, CT 06902-3602 Ph: (203) 276-4884 |
News Archive
While Zika remains a hot topic in the news, a new survey by Mayo Clinic reveals that Americans believe the country's most significant health care challenge is cancer.
Every year, in Germany alone, around 7,000 people wait for a new cornea to save their eyesight.
"The nation's uninsured — a growing class of people whose recession-fed ranks have swelled to 46.3 million — are central to the health care debate in Washington and the questions about how and whether to get them covered are as vexing and emotional as they come," USA Today reports. "While the nation waits for Congress and the White House to come up with answers, those who live without insurance say they are waiting scared."
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
A 64-year-old female patient with mediastinal metastasis recently became the first in Latin America to receive Elekta VMAT radiotherapy treatment enhanced with Monaco® planning software. Using the arc-based Elekta VMAT delivery method, Monaco displays how the radiation dose should be applied — its distribution and strength on the target. The result is a therapy that not only is rapid, but also fine-tuned to treat cancer and avoid healthy tissues.
› Verified 8 days ago
Dr. Max Shutran, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 29 Hospital Plz Ste 602, Stamford, CT 06902 Phone: 203-276-4884 Fax: 203-276-8418 | |
Carl Dila, M. D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 70 Mill River St, Ll3, Stamford, CT 06902 Phone: 203-324-3504 Fax: 203-969-1392 |